Stockscreener 앱 받기
369.35
1.38%
-5.3299
전일 마감가:
$374.68
열려 있는:
$374.49
하루 거래량:
185.99K
Relative Volume:
0.60
시가총액:
$10.90B
수익:
$417.30M
순이익/손실:
$225.03M
주가수익비율:
49.37
EPS:
7.4815
순현금흐름:
$237.38M
1주 성능:
-0.58%
1개월 성능:
+22.76%
6개월 성능:
+49.99%
1년 성능:
+164.44%
1일 변동 폭
$366.52
$377.24
1주일 범위
$363.27
$377.35
52주 변동 폭
$130.50
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
369.83 | 11.05B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
522.15 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
673.37 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.82 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.67 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.50 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
KRYSKrystal Biotech Inc Options - Finviz
Price to book forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech stock soars 16% in three months: Here's why - MSN
Krystal Biotech (KRYS) soars 3.4%: Is further upside left in the stock? - MSN
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Biotech Marvel with 31.9% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Krystal Biotech, Inc. Actuals & Estimates (FWB:4KB) - TradingView
Form 4 Krystal Biotech Inc For: 26 June By Investing.com - Investing.com South Africa
Krystal Biotech, Inc. Actuals & Estimates (MIL:1KRYS) - TradingView
Responsive Playbooks and the KRYS Inflection - Stock Traders Daily
Krystal Biotech EVP sells $347,270 in common stock - Investing.com UK
Krystal Biotech EVP sells $347,270 in common stock By Investing.com - Investing.com South Africa
Krystal Biotech (KRYS) EVP executes 10b5-1 option exercise and 1,000-share sale - Stock Titan
Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
High Growth Tech Stocks In US For June 2026 - simplywall.st
Krystal Biotech stock hits all-time high at 357.65 USD By Investing.com - Investing.com Australia
Krystal Biotech, Inc. Actuals & Estimates (MUN:4KB) - TradingView
Form 144 Krystal Biotech For: 25 June By Investing.com - Investing.com Australia
Krystal Biotech stock hits all-time high at 357.65 USD - Investing.com
KRYS (KRYS) option exercise: 1,000 shares to be sold on 06/25/2026 - Stock Titan
Krystal Biotech earnings outlook and chart levels, shares on Nasdaq watched by biotech investors - Ad-hoc-news.de
Price to book forward of Krystal Biotech, Inc. – SWB:4KB - TradingView
KRYS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Enterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Price to sales forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
Price to earnings forward of Krystal Biotech, Inc. – NASDAQ:KRYS - TradingView
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream - Insider Monkey
Krystal Biotech updates key Vyjuvek filing, shares trade firmly on Nasdaq - Ad-hoc-news.de
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels - Sahm
Krystal Biotech, Inc. (KRYS) Stock Analysis: A $10.26 Billion Market Cap Player in Gene Therapy with Strong Buy Ratings - DirectorsTalk Interviews
3 Biotech Firms With Major Potential Catalysts in the Coming Months - MarketBeat
3 US Pharmaceutical Stocks With Strong Margins And Earnings Growth - Sahm
TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403 - Moomoo
KRYS Maintained by TD Cowen -- Price Target Raised to $403 - GuruFocus
Krystal Biotech stock hits all-time high at 332.33 USD By Investing.com - Investing.com Nigeria
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead - Yahoo Finance
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead - The Motley Fool
Krystal Biotech Inc (KRYS) Institutional Confidence - TradingKey
Krystal Biotech Inc (KRYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Krystal Biotech Inc (KRYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Krystal Biotech Inc (KRYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Krystal Biotech Inc 주식 (KRYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thomas John Charles | EVP, General Counsel |
Jun 25 '26 |
Sale |
347.27 |
1,000 |
347,270 |
0 |
1.21%
3.14%
자본화:
|
볼륨(24시간):